

Amendments to the Specification:

Replace paragraph [0104] with the following amended paragraph:

[0104] Yet another embodiment includes a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula III, IV, IVc, V, VI, VII, VIII, or IX and a pharmaceutically acceptable carrier.


Replace paragraph [0105] with the following amended paragraph:

[0105] Another embodiment includes a method of treating a viral infection comprising administering to a subject a pharmaceutical composition ~~composition~~ comprising a therapeutically effective amount of any of the above-mentioned compounds, salts and tautomers thereof, and a pharmaceutically suitable carrier.

Replace paragraph [0114] with the following amended paragraph:

[0114] Figure 4 depicts dual functional HCV anti-virals and immune potentiators. TNF-alpha production is represented by black bars and IL-12 p40 is represented by gray bars, presented as the % of LPS (1 mg/ml) activity.

Modify Table 1, Example 20 as shown:

| | | | |
|----|--|--|-------|
| 20 | 1-[(4-chlorophenyl)methyl]-1H-imidazole-2-carbaldehyde thiosemicarbazone |  | 294.8 |
|----|--|--|-------|